TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04532892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meta 18.06 Day and Meta 18.06 Night
Description: 5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Meta 18.06 Day and Placebo Meta 18.06 Night
Description: 5 visits after screening (V0-V4), including questionnaires (V0-V2-V4), salivary tests (V0 \& V4) and calls for antistress advices and adverse events, concomitant medication reporting \& compliance (V1 \& V3)
Study: NCT02276482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Phophate
Description: Tedizolid Phophate 200 mg, IV and/or oral for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic comparator
Description: Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam
Description: In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam
Description: In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
Study: NCT04045457

Intervention type: PROCEDURE
Group type: OTHER
Intervention: dry needling
Description: insertion of needle into active myofascial trigger point
Study: NCT02267382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04619641

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Flow Nasal Cannula (HFNC)
Description: HFNC will be set at 30 L/min, with a temperature at 31° C and 100% of relative humidity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: CPAP will be delivered through a helmet (Castar Next, Intersurgical S.p.A., Mirandola, Italy), with an adjustable Positive End-Expiratory Pressure (PEEP) valve (2.5-20 cmH2O) set at 10 cmH2O (Intersurgical S.p.A., Mirandola, Italy). The helmet will be connected to a turbine-driven ventilator (Monnal T60, Air Liquide Medical Systems, Antony, France) set to deliver oxygen-air admixture at a continuous flow rate of 60 L/min, in order to improve CO2 wash out. No heated humidification will be applied to avoid the fog effect in the helmet
Study: NCT00113438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
Description: Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
Description: Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
Study: NCT02590718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: optimized postoperative management
Description: lying without the pillow for half an hour after lumbar puncture
Study: NCT01891006

Intervention type: OTHER
Group type: OTHER
Intervention: Standard wound dressing
Description: The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
Study: NCT01532830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: n-VNS
Study: NCT01662661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (suspension)
Description: Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (suspension)
Description: Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (tablet)
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-47910382 (tablet)
Description: Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
Study: NCT04351100

Intervention type: DRUG
Intervention: Diacerein
Description: Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.
Study: NCT03127475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
Study: NCT03452735

Intervention type: OTHER
Intervention: Questionnaire about fertility
Description: Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.

Intervention type: OTHER
Intervention: Questionnaire about fertility
Description: Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
Study: NCT04625023

Intervention type: OTHER
Intervention: Observational
Description: Retrospective cohorts and Prospective observation of standard clinical practice
Study: NCT02815709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oliceridine
Study: NCT03538535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Go/No-Go Active Learning (GOAL)
Description: Behavioral Activation psychotherapy adapted to engage go/no-go learning
Study: NCT03943095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Potassium Nitrate
Description: The test dentifrice contains 5% w/w potassium nitrate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stannous Fluoride
Description: The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
Study: NCT00768274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice daily (b.i.d.) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice daily (b.i.d.) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: RVX000222 twice daily (b.i.d.) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo twice daily (b.i.d.) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo twice daily (b.i.d.) for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo twice daily (b.i.d.) for 28 days
Study: NCT01674036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-682452
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-682452
Description: Capsules for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Genz-682452
Study: NCT01308216

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser therapy procedure
Description: Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low level laser therapy procedure
Description: Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
Study: NCT03143218

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RABIPUR®
Description: Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RTS,S/AS01
Description: Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC (SP+AQ) during the malaria transmission season One cycle of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC placebo
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
Study: NCT04596254

Intervention type: OTHER
Group type: OTHER
Intervention: Pomegranate Juice
Description: Collection of Mother's milk before and after juice consumption
Study: NCT02815709

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03177304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based IPT Training
Study: NCT03448146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Para-Toluenesulfonamide
Study: NCT04697758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.1 mg
Description: Single intravitreal injection of AXT107 0.1 mg/eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.25 mg
Description: Single intravitreal injection of AXT107 0.25 mg/eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.5 mg
Description: Single intravitreal injection of AXT107 0.5 mg/eye
Study: NCT02475408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amplatzer vascular plug
Study: NCT02815709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study: NCT00139659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Insulin
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Insulin
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Study: NCT03599934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle integrated functional exercise program
Description: Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home safety assessment
Description: Home safety assessment and modification that targets to reduce environmental risk factors of falls.
Study: NCT03548272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention with stent implantation
Description: PCI with BiOSS LIM C or rDES depending on the randomization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention with stent implantation
Description: PCI with BiOSS LIM C or rDES depending on the randomization
Study: NCT03317288

Intervention type: DEVICE
Group type: OTHER
Intervention: Dabir Air overlay
Description: The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
Study: NCT03856645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKG-0301
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKG-0301
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OKG-0301
Description: OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
Study: NCT02653066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealtheRx+
Description: Participant receives $5 bill with incentive check and blank consent form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HealtheRx++
Description: Participant receives $5 bill when they returned signed PRR consent form.
Study: NCT03343509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Oral
Description: Oral Metronidazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole Ointment
Description: Metronidazole Ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Ointment
Description: Placebo Ointment
Study: NCT03751098

Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide/Phenylephrine ophthalmic solution (TR/PE)
Description: Tropicamide 1%/phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Study: NCT00889785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention (disease management program)
Description: The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Will receive usual care and monthly phone calls as an active control.
Study: NCT00323609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
Study: NCT01058382

Intervention type: DRUG
Intervention: Progesterone Vaginal Suppositories
Description: Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer

Intervention type: DRUG
Intervention: Intramuscular Progesterone-in-Oil
Description: Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
Study: NCT03751098

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Eyewash administered with the Optejet microdose dispenser
Study: NCT03076671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care
Description: Palliative care training for community neurologists and use of telemedicine for team-based support of patients
Study: NCT03696212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant and pembrolizumab
Description: Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
Study: NCT02570308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMCgp100
Description: Bispecific soluble HLA-A2 restricted gp100-specific T-cell receptor fused to anti-CD3
Study: NCT01469988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
Study: NCT02953197

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG-PET guided radiation dose escalation
Description: Selective dose escalation
Study: NCT03066440

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers
Description: All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
Study: NCT03078842

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc tablets, 20 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablets, 10 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablets, 5 mg per day
Description: Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
Study: NCT03385876

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing and molecular diagnostic results, if any
Description: Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
Study: NCT03496532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biphasic stimulation
Description: Fixed 70Hz symmetrical biphasic pulses
Study: NCT00744653

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrochemotherapy
Description: Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
Study: NCT03334123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training and cycling
Description: First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling
Description: First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis.